期刊
WORLD JOURNAL OF GASTROENTEROLOGY
卷 21, 期 21, 页码 6572-6581出版社
BAISHIDENG PUBLISHING GROUP INC
DOI: 10.3748/wjg.v21.i21.6572
关键词
Hypoxia inducible factor-alpha; Mammalian target of rapamycin; Resveratrol; Th17 cells; Treg cells; Ulcerative colitis
资金
- Outstanding Doctoral Thesis Support Project of Guangdong Province [85514045]
- Technical Research and Development Project of Shenzhen [JCYJ20130402092657774]
- Medical Research Foundation of Guangdong Province [B2013347]
AIM: To determine the therapeutic efficacy of resveratrol on ulcerative colitis (UC) and its underlying mechanisms. METHODS: The mouse UC model was developed using 5% dextran sulfate sodium. Mice were randomly divided into four groups: normal control, UC model group, resveratrol low-dose group (RLD; 50 mg/kg per day), and resveratrol high-dose group (RHD; 100 mg/kg per day). RESULTS: The results showed that RLD regulates Treg/Th17 balance mainly through reducing the number of Th17 cells, whereas RHD regulates Treg/Th17 balance through both downregulating the number of Th17 cells and upregulating the number of Treg cells. Resveratrol can also regulate the level of plasma and intestinal mucosal cytokines including interleukin (IL)-10, transforming growth factor-beta 1, IL-6, and IL-17. The expressions of hypoxia inducible factor (HIF)-1 alpha, mammalian target of rapamycin (mTOR), and signal transducer and activator of transcription 3 were significantly decreased in the intestinal tissues of mice treated with resveratrol. CONCLUSION: The therapeutic efficacy of resveratrol in UC is dose dependent and closely associated with the regulation of Treg/Th17 balance and the HIF-1 alpha/mTOR signaling pathway.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据